» Articles » PMID: 20424299

Clinical Spectrum & Pathogenesis of Clostridium Difficile Associated Diseases

Overview
Specialty General Medicine
Date 2010 Apr 29
PMID 20424299
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Clostridium difficile is the major aetiological agent of antibiotic associated diarrhoea and colitis. The majority of hospitalized patients infected by C. difficile are asymptomatic carriers who serve as silent reservoirs for continued C. difficile contamination of the hospital environment. C. difficile associated disease (CDAD) is a serious condition with mortality up to 25 per cent in frail elderly people. C. difficile infection may present itself in several forms with both colonic and extracolonic manifestations. Several factors are involved in determining whether or not a patient develops C. difficile infection. These include factors related to the pathogen as well as the host. Transmission of C. difficile can be endogenous or exogenous. Colonization of the pathogen occurs when the gut flora gets disrupted due to various factors. The main virulence factors for CDAD are the two potent toxins: toxin A and toxin B which share 63 per cent of amino acid sequence homology and act on small guanosine triphosphate binding proteins. The emergence of the global hypervirulent C. difficile strain has been a cause of concern. Diagnosis of CDAD infection can be done by detection of C. difficile toxin in the stool specimen. Vancomycin is the drug of choice for severely ill patient, whereas metronidazole can be used for mild to moderately ill patients. Clinical spectrum, the factors precipitating CDAD, pathogenesis, diagnostic assay and treatment of the disease are reviewed.

Citing Articles

Research Progress on Detection of Pathogens in Medical Wastewater by Electrochemical Biosensors.

Chen B, He J, Tian K, Qu J, Hong L, Lin Q Molecules. 2024; 29(15).

PMID: 39124939 PMC: 11314202. DOI: 10.3390/molecules29153534.


Current and Ongoing Developments in Targeting Infection and Recurrence.

Cun W, Keller P, Pyne S Microorganisms. 2024; 12(6).

PMID: 38930588 PMC: 11205563. DOI: 10.3390/microorganisms12061206.


infection leading to fulminant colitis with toxic megacolon.

Rajack F, Medford S, Naab T Autops Case Rep. 2023; 13:e2023457.

PMID: 38034515 PMC: 10687841. DOI: 10.4322/acr.2023.457.


Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications.

Jain N, Umar T, Fahner A, Gibietis V Gut Microbes. 2023; 15(1):2232137.

PMID: 37431860 PMC: 10337487. DOI: 10.1080/19490976.2023.2232137.


, a New "Superbug".

Markovska R, Dimitrov G, Gergova R, Boyanova L Microorganisms. 2023; 11(4).

PMID: 37110267 PMC: 10140992. DOI: 10.3390/microorganisms11040845.